CoronaryAtlas logo
CoronaryAtlas
Interleukin-1β
Pathway / Plaque inflammation

Interleukin-1β

IL1Bprotein

Interleukin-1β is a central inflammasome-derived cytokine that orchestrates atherosclerotic plaque inflammation, promotes endothelial dysfunction and procoagulant activation, and accelerates cap degradation in unstable plaques.

Pathway placement
Cascade stepPlaque inflammation
Confidencehigh
RationaleNLRP3 inflammasome product; drives plaque inflammation, endothelial procoagulant expression, and plaque destabilization.
Also acts inEndothelial activation/erosion, Platelet activation, Cap degradation / rupture
Druggability
DruggableYes
Known drugs / candidates5
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000125538

Type I vs Type II discrimination

ScoresType-II-associated
R — rupture / Type-I
—
C — confounder / Type-II
67
A — assay feasibility
72
E — evidence strength
42
T1DI (composite)
7
Specificity differential (R−C)-52
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossn/a
3hypovolemia / dehydrationmag 2
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuren/a
6hypertensive emergencymag 2
7high-demand / peri-operative stressn/a
Coverage: 3/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 5 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(57)

Showing 40 of 57 linked references.